This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

3 Stocks Pulling The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 21 points (-0.1%) at 16,894 as of Friday, July 11, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,379 issues advancing vs. 1,581 declining with 154 unchanged.

The Health Care sector currently sits up 0.1% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include GlaxoSmithKline ( GSK), down 1.4%, AbbVie ( ABBV), down 1.1%, Baxter International ( BAX), down 0.8%, Alexion Pharmaceuticals ( ALXN), down 0.8% and Merck ( MRK), down 0.6%. Top gainers within the sector include Shire ( SHPG), up 4.8%, Grifols ( GRFS), up 1.6%, Intuitive Surgical ( ISRG), up 1.5%, St Jude Medical ( STJ), up 1.0% and Vertex Pharmaceuticals ( VRTX), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Novartis ( NVS) is one of the companies pushing the Health Care sector lower today. As of noon trading, Novartis is down $0.46 (-0.5%) to $89.35 on light volume. Thus far, 450,592 shares of Novartis exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $88.79-$89.48 after having opened the day at $88.87 as compared to the previous trading day's close of $89.81.

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. Novartis has a market cap of $220.4 billion and is part of the drugs industry. Shares are up 11.7% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts that rate Novartis a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Novartis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Perrigo ( PRGO) is down $3.58 (-2.4%) to $143.69 on average volume. Thus far, 762,423 shares of Perrigo exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $143.48-$145.91 after having opened the day at $145.25 as compared to the previous trading day's close of $147.27.

Perrigo is buying Canam Care as of Jan 2012 for $36. Perrigo has a market cap of $19.8 billion and is part of the drugs industry. Shares are down 4.0% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts that rate Perrigo a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Perrigo as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Perrigo Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Mylan ( MYL) is down $0.52 (-1.0%) to $50.19 on light volume. Thus far, 1.0 million shares of Mylan exchanged hands as compared to its average daily volume of 4.1 million shares. The stock has ranged in price between $49.95-$50.80 after having opened the day at $50.62 as compared to the previous trading day's close of $50.70.

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. Mylan has a market cap of $18.7 billion and is part of the drugs industry. Shares are up 16.8% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Mylan a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mylan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Mylan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs